Alvotech Beginning To Take Flight As Product Sales Treble In H1
Three Filings In Major Markets Slated For This Year, Including Golimumab
Driven by increased orders, Alvotech is bullish on its US adalimumab biosimilar moving into 2025, as it also look forward to the US launch for its Stelara biosimilar early next year.
